Biomarker discrepancies following chimeric antigen receptor T cells: implications in B-cell acute lymphoblastic leukemia.

Chelsea Lamplugh¹, Julie Ma², Bonnie Yates², Hao-Wei Wang³, Constance M Yuan³, Chloe Hoang², Sara K Silbert², Tanvi Verma⁴, David Peske⁴, Benjamin L Green⁵, Ilan Kirsch⁵, Challice Bonifant⁶, Nirali N Shah⁷

¹Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Pediatric Oncology, Johns Hopkins Children's Center, Baltimore, MD.

²Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

³Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD.

⁴Johns Hopkins School of Medicine, Department of Pathology, Baltimore, MD.

⁵Adaptive Biotechnologies, Seattle, WA.

⁶Department of Pediatric Oncology, Johns Hopkins Children's Center, Baltimore, MD.

⁷Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Nirali.Shah@som.umaryland.edu.

PubMed DOI

Abstract

Not available.

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.